Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29122934.
- Also identified by DOI 10.1158/1078-0432.CCR-17-2884 and PMC identifier 5754255.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoints have been a focus of immunotherapy in the recent decade. Killer cell immunoglobulin-like receptors (KIR) and their cognate human leukocyte antigen (HLA) class I ligands have evolved as checkpoints to ensure self-tolerance of natural killer cells. Both KIR and HLA genetic profiles are potential biomarkers of immunotherapy outcome. <i>Clin Cancer Res; 24(1); 3-5. ©2017 AACR</i><i>See related article by Erbe et al., p. 189</i>.
Medical subject headings
- Genotype
- Neuroblastoma